Between 2000 and 2014, gp96 and HSP70–peptide-based vaccines derived from autologous tumor lysates were clinically applied in phase I to phase III clinical trials in different tumor entities including late stage melanoma (42) either alone or in combination with GM-CSF and IFN-γ (43–48), metastatic colon carcinoma (49), renal cell carcinoma (50), gastric carcinoma (51, 52), pancreatic carcinoma (53), chronic myeloid leukemia (54), and glioblastoma (55) (Table 1). The gene discussed is HSPA1A; the disease is exocrine pancreatic carcinoma.